...
首页> 外文期刊>Melanoma research >Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.
【24h】

Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.

机译:来自非洲黑人和其他皮肤黑素瘤亚组的黑素瘤中EGFR-NRAS-BRAF途径的突变分析。

获取原文
获取原文并翻译 | 示例

摘要

Earlier studies have shown frequent mutations in the BRAF and NRAS genes in cutaneous melanoma, but these alterations have not been examined in the rare category of melanoma from black Africans. Moreover, the frequency of epidermal growth factor receptor (EGFR) mutations in melanocytic tumors is not known. We therefore examined 165 benign and malignant melanocytic lesions (including 118 invasive melanomas and 18 metastases collected as consecutive cases from various time periods and from two different pathology departments; the 51 nodular melanomas were randomly selected from a larger, consecutive, population-based series of nodular melanomas) with respect to alterations in the EGFR, BRAF and NRAS genes. Mutations in EGFR (exons 18-21) were not detected. EGFR protein expression was observed in a subgroup of melanomas, but without associations with clinicopathologic phenotype or prognosis. Cytoplasmic EGFR expression was, however, significantly increased from benign nevi to melanomas. Mutations in BRAF and NRAS were detected in superficial melanoma (25 and 29%, respectively), nodular melanoma (29 and 28%, respectively) and lentigo maligna melanoma (15 and 16%, respectively). In a series of melanomas from black Africans (n=26), only two BRAF mutations (8%) were found, both being different from the common T1799A substitution. Moreover, melanomas from black Africans exhibited mutations in NRAS exon 1 only (12%), whereas NRAS exon 2 mutations were predominant in melanomas from Caucasians. Thus, the frequencies of BRAF and NRAS mutations were particularly low in melanomas from black Africans, supporting a different pathogenesis of these tumors.
机译:较早的研究表明,皮肤黑色素瘤中BRAF和NRAS基因频繁突变,但在非洲黑人罕见的黑色素瘤类别中未检查到这些改变。此外,尚不知道黑素细胞瘤中表皮生长因子受体(EGFR)突变的频率。因此,我们检查了165例良性和恶性黑素细胞病变(包括从不同时期和两个不同病理科连续收集的118例侵袭性黑色素瘤和18处转移瘤; 51例结节性黑色素瘤是从较大的,连续的,基于人群的系列研究中随机选择的)结节性黑色素瘤)。未检测到EGFR突变(外显子18-21)。在一个黑色素瘤亚组中观察到EGFR蛋白表达,但与临床病理表型或预后无关。但是,从良性痣到黑色素瘤,细胞质EGFR的表达显着增加。在浅表黑色素瘤(分别为25%和29%),结节性黑色素瘤(分别为29%和28%)和恶性扁豆黑色素瘤(分别为15%和16%)中检测到BRAF和NRAS突变。在来自非洲黑人的一系列黑色素瘤(n = 26)中,仅发现了两个BRAF突变(8%),两者均不同于常见的T1799A替代。此外,来自非洲黑人的黑色素瘤仅在NRAS外显子1中表现出突变(12%),而在白种人的黑色素瘤中NRAS外显子2突变居多。因此,在来自非洲黑人的黑色素瘤中,BRAF和NRAS突变的频率特别低,这支持了这些肿瘤的不同发病机理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号